CTRI/2022/07/044203
Recruiting
Phase 3
A Prospective, Randomized, Double-Blind, Two-Arm, Placebo-Controlled Comparative Clinical Study to Evaluate the Safety and Efficacy of Liv.52 Tablets in Alcoholic Liver Disease
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Himalaya Wellness Company
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patients of either gender aged \>18 to \<65 years.
- •2\.Patients diagnosed as Alcoholic Liver Disease (ALD) ? on the basis of all of the following criteria:
- •a.Patient with a history of alcohol use based on AUDIT (Alcohol Use Disorders Inventory Test) questionnaire (A total sum of \>8 for men and \>4 for women)
- •b.Ongoing consumption of Alcohol or Active alcohol use until 4 weeks prior to screening.
- •c.Patients with elevated liver function test (ALT and AST \>1\.5 times of upper limit of normal (ULN) \& GGT \> 2\.5 ULN)
- •d.Ultrasound evidence of fatty liver (steatosis) and / Hepatitis.
- •e.Maddrey Discriminant function (DF) less than 32\.
- •3\.Patient has not participated in a similar investigation in past four weeks.
- •4\.Presenting with one or more clinical symptoms of Alcoholic liver disease like nausea, loss of appetite, jaundice, fatigue, abdominal discomfort, increased thirst, swelling, weight loss (due to loss of proximal muscle mass), weakness, mood swings, bleeding gums, dysphagia, Weight gain (due to ascites), confusion, amenorrhea etc
- •5\.Ability to understand and willing to give a written informed consent prior to any study\-related procedures and ready to follow and in agreement to visits as per the study assessment visits
Exclusion Criteria
- •1\.Severe alcoholic hepatitis with cirrhosis or any of its complications (e.g., Hepatocellular Carcinoma, Portal hypertension, uncontrolled infection, Acute Kidney Injury etc.)
- •2\.Patient with other cause of Chronic Liver Disease (Nonalcoholic fatty liver disease (NAFLD), Autoimmune Liver Disease, Wilson Disease, Viral Hepatitis (HBV, HCV), hemochromatosis) and metabolic syndrome
- •3\.Hepatic disorders due to cardiac causes, inherited metabolic causes.
- •4\.Participants with active viral hepatitis.
- •5\.Undergoing active treatment for alcohol withdrawal syndrome (AWS) at the study entry.
- •6\.Participants on hepatotoxic medications like antitubercular medication, antiviral medication.
- •7\.Severe cases of ascites, (however, Grade I \& II as per CTCAE criteria can be enrolled.) hepatic encephalopathy, varices, or bleeding.
- •8\.Subjects with elevated liver function test ALT and AST \> 5 times of upper limit of normal (ULN)
- •9\. Patients are on treatment for AUD (Alcohol Use Disorder)
- •10\. Pregnant or lactating women or who don’t want to follow the effective contraception measures.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 3
A clinical study to evaulate the efficacy and safety of Liv.52 DS tablets in Fatty Liver Disease.Health Condition 1: E70-E88- Metabolic disordersCTRI/2022/03/041481Himalaya Wellness Company
Completed
Not Applicable
A Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Two Proprietary Herbal Medicines as Mono Therapy and as Combination Therapy in Adult Subjects with Moderate to Severe Psoriasis.Health Condition 1: L409- Psoriasis, unspecifiedCTRI/2014/01/004277Dr JRKs Siddha Research and Pharmaceuticals Private Limited42
Completed
Phase 3
A clinical trial to study the effects of two drugs, Dynapar QPS and placebo topical solution in patient suffering from osteoarthritis.Health Condition 1: null- Osteoarthritis of kneeCTRI/2015/02/005510Troikaa Pharmaceuticals Limited212
Completed
Phase 2
Clinical study to evaluate and compare the immunogenicity and safety of Tetanus vaccine of Cadila Healthcare Ltd. vs Tetanus vaccine of Serum Institute of India Ltd. in healthy subjects and subjects with clean minor woundsCTRI/2015/05/005740Cadila Healthcare Ltd283
Recruiting
Phase 2
Clinical study to compare the immune response and safety of trivalent flu vaccine manufactured by Cadila Healthcare Ltd. with a trivalent flu vaccine marketed in India in healthy adultsHealth Condition 1: Z23- Encounter for immunizationCTRI/2015/09/006208Cadila Healthcare Ltd348